Fractyl Health has completed randomization in REMAIN-1, its sham-controlled pivotal cohort evaluating the Revita endoscopic procedure for weight maintenance...

MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of its oral...

Phase 2 platform funding of £4.2 million is backing TOCSINS, a multicountry trial evaluating oral snakebite therapies, with Ophirex...

MindRank has dosed the first patient in MOBILE, a Phase III, multicenter, randomized, double-blind, placebo-controlled trial of MDR-001, an...

In a Phase 2b randomized, dose-finding study of 148 ambulatory adults with aging-related frailty, intravenous laromestrocel improved six-minute walk...

Phase 3 COMPETE met its primary endpoint, with 177Lu-edotreotide delivering a clinically and statistically significant improvement in progression-free survival...

TPST-2003 delivered a 100% complete response rate among the six efficacy-evaluable patients in the ongoing REDEEM-1 Phase 1/2a trial,...

The pharmaceutical industry has long grappled with the cognitive dissonance of drug development—the tension between data-driven insights and the...

Crescent Biopharma has dosed the first patient in ASCEND (NCT07335497), a global, open-label Phase 1/2 trial of CR-001, a...

In a small Phase 1b study of six relapsed/refractory multiple myeloma patients, continuous low‑dose lenalidomide (STAR-LLD) produced one complete...